Clinical Trials
9 trialsNCT03323398 2024-07-31
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
ModernaTX, Inc.
Phase 1/2 Terminated
NCT03439085 2024-07-09
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03015129 2024-02-06
A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02807454 2023-02-21
FUSIONMM-003
Celgene
Phase 2 Terminated
NCT03162224 2022-08-25
Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
MedImmune LLC
Phase 1/2 Completed
NCT02369874 2021-02-10
EAGLE
AstraZeneca
Phase 3 Completed
NCT02207530 2020-09-29
Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
AstraZeneca
Phase 2 Completed
NCT02319044 2020-09-29
Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck
AstraZeneca
Phase 2 Completed
NCT03000452 2018-10-16
FUSION-MM-005
Celgene
Phase 2 Completed